Autoimmune (IgG4-related) pancreatitis
AIP · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Steroid-responsive fibroinflammatory pancreatitis; type 1 is the pancreatic manifestation of IgG4-related disease, type 2 is duct-centric and associated with IBD. A key mimic of pancreatic cancer.
Figures & algorithms
Red flags
- Features suggesting malignancy (discrete mass, weight loss, rising CA19-9)
- Cholangitis with obstructive jaundice
- Failure to respond to steroids (reconsider cancer)
- Multi-organ IgG4 disease progression
Assessment
Differential diagnosis
- Pancreatic adenocarcinoma
- Chronic (alcohol-related) pancreatitis
- Cholangiocarcinoma (if biliary strictures)
- Primary sclerosing cholangitis
- Lymphoma
Investigations
- Serum IgG4 (elevated in type 1)
- Cross-sectional imaging: diffuse 'sausage' pancreas with rim/halo, delayed enhancement
- MRCP/ERCP: long/multifocal main pancreatic duct strictures without upstream dilatation
- EUS-guided biopsy (storiform fibrosis, lymphoplasmacytic infiltrate, IgG4+ plasma cells)
- Assess other organ involvement (biliary, renal, salivary, retroperitoneal fibrosis)
Management
- Suspect AIP in painless obstructive jaundice or a pancreatic mass with raised IgG4 or other-organ involvement
- Critically exclude pancreatic/biliary malignancy — AIP is a cancer mimic
- Combine imaging, serology, histology and other-organ involvement (e.g. ICDC criteria) to diagnose
- Obtain tissue (EUS biopsy) where malignancy cannot be confidently excluded
- Induce remission with corticosteroids — most patients respond rapidly
- Relieve biliary obstruction with stenting if significant jaundice/cholangitis
- Taper steroids over weeks to months with clinical and biochemical monitoring
- Use a steroid-sparing immunomodulator or rituximab for relapse/maintenance in type 1
- Monitor for and treat exocrine and endocrine insufficiency
- Screen for and manage associated IgG4 disease in other organs
- Arrange long-term follow-up given relapse tendency
Drugs & doses
Prednisolone 0.6–0.8 mg/kg/day PO (typically 30–40 mg) then taper
Azathioprine 2–2.5 mg/kg/day PO (maintenance/relapse)
Rituximab (refractory/relapsing type 1, specialist)
Pancreatic enzyme replacement if exocrine insufficiency
Disposition
Pancreaticobiliary MDT; hepatology/gastroenterology follow-up for immunosuppression and relapse surveillance.
Complications & pitfalls
- Misdiagnosis as pancreatic cancer (unnecessary surgery) or vice versa
- Biliary strictures and cholangitis
- Exocrine and endocrine (diabetes) insufficiency
- Relapse requiring immunosuppression
- Steroid side effects
Exam pearls
- A dramatic steroid response supports AIP, but exclude cancer first — never steroid-trial a possible malignancy without tissue
- Raised IgG4 is suggestive but not diagnostic; it can be normal in type 2 and mildly raised in cancer
- Type 2 AIP is associated with inflammatory bowel disease
- Relapse is common in type 1; maintenance immunosuppression or rituximab may be needed
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.
